|
Re: ASCO: breakthrough finding in her2+ breast cancer--preventing resistance to anti
The way I understood this is, that Herceptin binds to receptors on cancer cells, thus stopping them from dividing. While Herceptin is bound to cell, your own immune system recognizes cell as defective and killer cells and phages come to destroy and eat it.
The pathology report from my mastectomy tissue would support this, as lots of phages were found but no more cancer cells.
__________________
Dx 9/17/2015, IDC/Paget's, Left, 2cm, Stage IIA, Grade 3, 0/3 nodes, ER-/PR-, HER2+ at age 57
Surgery 10/6/2015 Lymph node removal: Sentinel
Chemotherapy start 10/19/2015 Carboplatin (Paraplatin), Taxotere (docetaxel)
Targeted Therapy start 10/19/2015 Herceptin (trastuzumab), Perjeta (pertuzumab)
Surgery 02/23/2016 MX Left, PMX Right
|
Threaded Mode